Materials Required but not Supplied

1. Micropipettes (< 3% CV) and tips to deliver 5-1000 µL.
2. Calibrated measures.
3. Tubes (1 mL) for sample dilution.
4. Wash bottle, automated or semi-automated microtiter plate washing system.
5. Microtiter plate reader capable of reading absorbance at 450/650 nm.
6. Bidistilled or deionised water, paper towels, pipette tips and timer.

Procedure Notes

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.

6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.

7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

Preparation of Component

Dilute/ disolve	Component	with	Diluent	Rela-tion	Remarks	Storage	Stability
10 mL	Wash Buffer*	Up to 200 mL	Bidist. water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	2 w

*. Prepare Wash Buffer before starting assay procedure.

Test Procedure

1	Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used.
2	**QUALITATIVE ELISA TEST FORMAT** Pipette 10 µL of ready-to use Negative Control, Reactive Control, and Samples into the respective wells of microtiter plate. Wells A1: Negative Control B1: Negative Control C1: Reactive Control D1 and on:. Sample (Serum/Plasma)
3	Cover the plate with adhesive film. Briefly mix contents by gently shaking the plate. Incubate 60 min at room temperature (18-25°C).
4	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
5	Pipette 100 µL of ready-to use Peroxidase Conjugate into each well.
6	Cover the plate with adhesive film. Incubate 60 min at room temperature (18- 25°C).
7	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
8	Pipette 100 µL of TMB Substrate Solution into each well.
9	Incubate 20 min (without adhesive foil.) at room temperature (18-25°C) in the dark.
10	Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow
11	Measure optical density with a photometer at 450/650 nm within 30 min after pipetting of the Stop Solution.

Interpretation Of Results

For the run to be valid, the OD_{450} nm of Positive Control should be ≥ 1.00 and the OD450/650 nm of each Negative Control should be <0.200 0, if not, improper technique or reagent deterioration may be suspected and the run should be repeated.

The results are evaluated by a cut-off value which is estimated by multiplying the mean OD450/650 nm of the negative controls by 3.

E.g.;

If "Sample $OD_4$450/650 the mean OD450 /650 of Negative Controls" is ≥3, the sample is POSITIVE If "Sample OD450/650 the mean OD450/650 of Negative Controls" is <3, the sample is NEGATIVE

REFERENCES

1.Ipilimumab (Yervoy) Prolongs Survival In Advanced Melanoma
Serious Side Effects and a Hefty Price Tag May Limit Its Use P T. 2012 Sep; 37(9): 503-511, 530.

2. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Sep 23;363(13):1290.

3. Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma Yale J Biol Med. 2011 Dec; 84(4): 381–389. Published online 2011 Dec.

4. Ipilimumab-induced colitis in patients with metastatic melanoma Melanoma Res. 2015 Aug;25(4):321-7. doi: 10.1097/CMR.0000000000000165.

5. Ipilimumab in the treatment of metastatic melanoma: management of adverse events Onco Targets Ther. 2014; 7: 203–209. Published online 2014 Feb 19. doi: 10.2147/ OTT.S57335

6. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012 Sep;37(9):503-30.

7. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Eur J Cancer. 2012 Jan;48(2):237-42. doi: 10.1016/j.ejca.2011.09.018. Epub 2011 Oct 24.

8. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 1291(1): 1–13. Published online 2013 Jun 17. doi: 10.1111/nyas.12180

9. Ipilimumab (Yervoy) and the TGN1412 catastrophe.
Immunobiology. 2012 Jun;217(6):583-9. doi: 10.1016/j.imbio.2011.07.005. Epub 2011 Jul 7.

10. Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors Cancer Biother Radiopharm. 2010 Dec; 25(6): 601–613. doi: 10.1089/cbr.2010.0865

11. Association of Ipilimumab Therapy for Advanced Melanoma With Secondary Adrenal Insufficiency: A Case Series. Endocr Pract. Author manuscript; available in PMC 2014 Apr 23.Endocr Pract. 2012 May-Jun; 18(3): 351–355. doi: 10.4158/EP11273.OR